Sangamo Therapeutics, Inc.
SGMOFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
58
Cost of Revenue
0
Gross Profit
58
Gross Margin
100.0%
Operating Income
-104
Operating Margin
-179.9%
Net Income
-98
Net Margin
-169.4%
EPS (Basic)
$-0.49
EPS (Diluted)
$-0.49
EBITDA
-89
EBITDA Margin
-154.1%
2023
12/31/2023
Revenue
176
Cost of Revenue
0
Gross Profit
176
Gross Margin
100.0%
Operating Income
-274
Operating Margin
-155.5%
Net Income
-258
Net Margin
-146.3%
EPS (Basic)
$-1.48
EPS (Diluted)
$-1.48
EBITDA
-97
EBITDA Margin
-54.9%
2022
12/31/2022
Revenue
111
Cost of Revenue
12
Gross Profit
99
Gross Margin
89.1%
Operating Income
-201
Operating Margin
-180.8%
Net Income
-192
Net Margin
-172.8%
EPS (Basic)
$-1.25
EPS (Diluted)
$-1.25
EBITDA
-189
EBITDA Margin
-170.0%
2021
12/31/2021
Revenue
111
Cost of Revenue
0
Gross Profit
111
Gross Margin
100.0%
Operating Income
-183
Operating Margin
-165.6%
Net Income
-178
Net Margin
-161.1%
EPS (Basic)
$-1.23
EPS (Diluted)
$-1.23
EBITDA
-166
EBITDA Margin
-149.7%
2020
12/31/2020
Revenue
118
Cost of Revenue
181
Gross Profit
-62
Gross Margin
-52.8%
Operating Income
-130
Operating Margin
-109.6%
Net Income
-121
Net Margin
-102.4%
EPS (Basic)
$-0.90
EPS (Diluted)
$-0.90
EBITDA
-124
EBITDA Margin
-104.8%